LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 1-Year High – Here’s What Happened
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals Inc’s Lock-Up Period Will Expire on March 10th (NASDAQ:LBRX)
LB Pharmaceuticals to Participate in Upcoming March Investor Events
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Announces $100.0 Million Private Placement
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
LB Pharma valued at $382 million as shares jump in New York debut
LB Pharmaceuticals raises $285 million in US IPO
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering